Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

BACKGROUND: The proteasome inhibitor bortezomib can inhibit activation of the transcription factor NF-κB, a mechanism implicated in its anti-neoplastic effects observed in mantle cell lymphoma (MCL). However, NF-κB can be activated through many distinct mechanisms, including proteasome independent p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, David T, Young, Ken H, Kahl, Brad S, Markovina, Stephanie, Miyamoto, Shigeki
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408930/
https://www.ncbi.nlm.nih.gov/pubmed/18489772
http://dx.doi.org/10.1186/1476-4598-7-40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408930/
https://www.ncbi.nlm.nih.gov/pubmed/18489772
http://dx.doi.org/10.1186/1476-4598-7-40

Ejemplares similares